Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates

Mucosal delivery of a vectored RSV vaccine is safe and elicits protective immunity in rodents and nonhuman primates

Respiratory Syncytial Virus (RSV) is a leading cause of severe respiratory disease in infants and the elderly. No vaccine is presently available to address this major unmet medical need. We generated a new genetic vaccine based on chimpanzee Adenovirus (PanAd3-RSV) and Modified Vaccinia Ankara RSV (...

Full description

Bibliographic Details
Main Authors:	Angiolo Pierantoni, Maria Luisa Esposito, Virginia Ammendola, Federico Napolitano, Fabiana Grazioli, Adele Abbate, Mariarosaria del Sorbo, Loredana Siani, Anna Morena D'Alise, Alessandra Taglioni, Gemma Perretta, Antonio Siccardi, Elisa Soprana, Maddalena Panigada, Michelle Thom, Elisa Scarselli, Antonella Folgori, Stefano Colloca, Geraldine Taylor, Riccardo Cortese, Alfredo Nicosia, Stefania Capone, Alessandra Vitelli
Format:	Article
Language:	English
Published:	Elsevier 2015-01-01
Series:	Molecular Therapy: Methods & Clinical Development
Online Access:	http://www.sciencedirect.com/science/article/pii/S2329050116300304

Similar Items

Chimpanzee adenoviral vectors as vaccines – challenges to move the technology into the fast lane
by: Alessandra Vitelli, et al.
Published: (2017-12-01)

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.
by: Green, C, et al.
Published: (2015)

Personalized Cancer Vaccines Go Viral: Viral Vectors in the Era of Personalized Immunotherapy of Cancer
by: Laura Seclì, et al.
Published: (2023-11-01)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates
by: Capone, S, et al.
Published: (2010)

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates.
by: Capone, S, et al.
Published: (2010)

Humoral and cellular immunity to RSV in infants, children and adults
by: Green, C, et al.
Published: (2018)

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling
by: Margherita Passariello, et al.
Published: (2019-09-01)

Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.
by: Green, C, et al.
Published: (2015)

Vaccination to conserved influenza antigens in mice using a novel Simian adenovirus vector, PanAd3, derived from the bonobo Pan paniscus.
by: Alessandra Vitelli, et al.
Published: (2013-01-01)

Generation of a Retargeted Oncolytic <i>Herpes</i> Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance
by: Chiara Gentile, et al.
Published: (2021-12-01)

Entanglement entropy in conformal quantum mechanics
by: Michele Arzano, et al.
Published: (2023-10-01)

MHC class II invariant chain–adjuvanted viral vectored vaccines enhances T cell responses in humans
by: Esposito, I, et al.
Published: (2020)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
by: Margherita Passariello, et al.
Published: (2020-08-01)

A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C.
by: Federico Napolitano, et al.
Published: (2020-07-01)

Correction: Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting
by: Daniela Boselli, et al.
Published: (2023-09-01)

Time- and cost-effective production of untagged recombinant MVA by flow virometry and direct virus sorting
by: Daniela Boselli, et al.
Published: (2023-07-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC T CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL ADENOVIRAL VECTORS FROM RARE SEROTYPES
by: Folgori, A, et al.
Published: (2009)

The θ-angle and axion physics of two-color QCD at fixed baryon charge
by: Jahmall Bersini, et al.
Published: (2022-11-01)

A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory
by: Swadling, L, et al.
Published: (2014)

Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans
by: Kelly, C, et al.
Published: (2016)

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade
by: Anna Morena D’Alise, et al.
Published: (2019-06-01)

Chronic Hepatitis C Virus infection subverts vaccine induced T-cell immunity in humans.
by: Kelly, C, et al.
Published: (2016)

P11-13. Antigen presentation and immune priming of CCR5-ECL1 receptor in Peyer's patches B cells
by: Siccardi A, et al.
Published: (2009-10-01)

Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection
by: Gerretsen, H, et al.
Published: (2018)

Nasal Microbiota in RSV Bronchiolitis
by: Serena Schippa, et al.
Published: (2020-05-01)

Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer
by: Anna Morena D’Alise, et al.
Published: (2023-04-01)

Strong immunogenicity of heterologous prime-boost immunizations with the experimental vaccine GRAd-COV2 and BNT162b2 or ChAdOx1-nCOV19
by: Chiara Agrati, et al.
Published: (2021-11-01)

A highly immunogenic novel genetic vaccine against HCV
by: Del Sorbo, M, et al.
Published: (2012)

Generation of a Novel Mesothelin-Targeted Oncolytic <i>Herpes</i> Virus and Implemented Strategies for Manufacturing
by: Guendalina Froechlich, et al.
Published: (2021-01-01)

Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine
by: Rosa Bartolomeo, et al.
Published: (2024-03-01)

Integrity of the Antiviral STING-mediated DNA Sensing in Tumor Cells Is Required to Sustain the Immunotherapeutic Efficacy of <i>Herpes Simplex</i> Oncolytic Virus
by: Guendalina Froechlich, et al.
Published: (2020-11-01)

Enhanced vaccine-induced CD8+ T cell responses to malaria antigen ME-TRAP by fusion to MHC class ii invariant chain.
by: Spencer, A, et al.
Published: (2014)

Global molecular diversity of RSV – the “INFORM RSV” study
by: Annefleur C. Langedijk, et al.
Published: (2020-06-01)

VENUS, a Novel Selection Approach to Improve the Accuracy of Neoantigens’ Prediction
by: Guido Leoni, et al.
Published: (2021-08-01)

PHASE I TRIAL OF A HIGHLY IMMUNOGENIC AND DURABLE T-CELL VACCINE FOR HEPATITIS C VIRUS BASED ON NOVEL, RARE, ADENOVIRAL VECTORS
by: Barnes, E, et al.
Published: (2011)

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.
by: Colloca, S, et al.
Published: (2012)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
by: Harrison C. Bergeron, et al.
Published: (2022-10-01)

Highly-immunogenic virally-vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
by: Swadling, L, et al.
Published: (2016)

Highly immunogenic virally vectored T-cell vaccines cannot overcome subversion of the T-cell response by HCV during chronic infection
by: Swadling, L, et al.
Published: (2016)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
by: Freek Cox, et al.
Published: (2023-03-01)